Vaccine

Abstract

Vaccine comprising a peptide bound to a pharmaceutically acceptable carrier, said peptide having the amino acid sequence (SEQ ID NO: 1) (X 1 ) m  (X 2 ) n  (X 3 ) o  X 4  X 5  H P X 6 (Formula I), for treating and/or preventing a physical disorder associated with the renin-activated angiotensin system, wherein X 1 is G or D, X 2 is A, P, M, G, or R, X 3 is G, A, H, or V, X 4 is S, A, D, or Y, X 5 is A, D, H, S, N, or I, X 6 is A, L or F, wherein m, n and o are independently 0 or 1 under the premise that when o is 0 m and n are 0 and when n is 0 m is 0, and wherein the peptide is not DRVYIHPF (SEQ ID NO:4).

1 . A pharmaceutical composition for inducing an immune response comprising a peptide bound to a pharmaceutically acceptable carrier, wherein said peptide has the amino acid sequence 
       
         
           
                 
               
                   (SEQ ID NO: 1) 
                 
                 
                 
               
                   (X 1 ) m  (X 2 ) n  (X 3 ) o  X 4  X 5  HP X 6   
                   (Formula I), 
                 
             
                
               
            
             
                
               
            
           
         
         wherein
 X 1  is G or D, 
 X 2  is A, P, M, G, or R, 
 X 3  is G, A, H, or V, 
 X 4  is 5, A, D, or Y, 
 X 5  is A, D, H, S, N, or I, 
 X 6  is A, L or F, 
 
         wherein m, n and o are independently 0 or 1 under the premise that when o is 0 m and n are 0 and when n is 0 m is 0, and wherein the peptide is not DRVYIHPF (SEQ ID NO:4), and wherein said pharmaceutical composition is for treating and/or preventing a physical disorder associated with the rennin-activated angiotensin system. 
       
     
     
         2 . The pharmaceutical composition according to  claim 1 , wherein the peptide is selected from the group consisting of GRVYIHPF (SEQ ID NO:6), DPVYIHPF (SEQ ID NO:7), DMVYIHPF (SEQ ID NO:8), DGVYIHPF (SEQ ID NO:9), DAVYIHPF (SEQ ID NO:10), DRGYIHPF (SEQ ID NO:11), DRAYIHPF (SEQ ID NO:12), DRHYIHPF (SEQ ID NO:13), DRVAIHPF (SEQ ID NO:14), DRVSIHPF (SEQ ID NO:15), DRVDIHPF (SEQ ID NO:16), DRVYAHPF (SEQ ID NO: 17), DRVYNHPF (SEQ ID NO:18), DRVYDHPF (SEQ ID NO:19), DRVYHHPF (SEQ ID NO:20), DRVYSHPF (SEQ ID NO:21), DRVYIHPA (SEQ ID NO:23), DRVYIHPL (SEQ ID NO:25), DAAYIHPF (SEQ ID NO:27), DRAAIHPF (SEQ ID NO:28), DRVAAHPF (SEQ ID NO:29), DRAYAHPF (SEQ ID NO:30), DRAAAHPF (SEQ ID NO:31), DAAAIHPF (SEQ ID NO:34), DAGYIHPF (SEQ ID NO:37), DAHYIHPF (SEQ ID NO:38), DPGYIHPF (SEQ ID NO:39), DPAYIHPF (SEQ ID NO:40), DMGYIHPF (SEQ ID NO:41), DMAYIHPF (SEQ ID NO:42), DMHYIHPF (SEQ ID NO:43), DGGYIHPF (SEQ ID NO:44), DGAYIHPF (SEQ ID NO:45), DGHYIHPF (SEQ ID NO:46), DPVAIHPF (SEQ ID NO:47), DMVAIHPF (SEQ ID NO:49), DMVSIHPF (SEQ ID NO:50), DRGAIHPF (SEQ ID NO:51), DRHAIHPF (SEQ ID NO:52), DRGYAHPF (SEQ ID NO:53), DRGYDHPF (SEQ ID NO:54), DRGYHHPF (SEQ ID NO:55), DRGYSHPF (SEQ ID NO:56), DRGYNHPF (SEQ ID NO:57), DRAYDHPF (SEQ ID NO:58), DRAYHHPF (SEQ ID NO:59), DRAYSHPF (SEQ ID NO:60), DRAYNHPF (SEQ ID NO:61), DRHYAHPF (SEQ ID NO:62), DRHYSHPF (SEQ ID NO:63), DRHYNHPF (SEQ ID NO:64), DRHYDHPF (SEQ ID NO:65), DRHYHHPF (SEQ ID NO:66), DRGADHPF (SEQ ID NO:68), DRVAHHPF (SEQ ID NO:70), DRHADHPF (SEQ ID NO:71), GRGAIHPF (SEQ ID NO:72), DPGAIHPF (SEQ ID NO:75), DPGSIHPF (SEQ ID NO:77), DMGAIHPF (SEQ ID NO:78), DMGSIHPF (SEQ ID NO:79), GPGYIHPF (SEQ ID NO:80), GPGSIHPF (SEQ ID NO:82), GMGSIHPF (SEQ ID NO:83), DRGSIHPF (SEQ ID NO:84), DPHAIHPF (SEQ ID NO:85), DMHAIHPF (SEQ ID NO:86), GPHAIHPF (SEQ ID NO:87), GMHSIHPF (SEQ ID NO:90), PVYIHPF (SEQ ID NO: 91), MVYIHPF (SEQ ID NO: 92), GVYIHPF (SEQ ID NO: 93), AVYIHPF (SEQ ID NO: RGYIHPF (SEQ ID NO: 95), RAYIHPF (SEQ ID NO: 96), RHYIHPF (SEQ ID NO: 97), RVAIHPF (SEQ ID NO: 98), RVSIHPF (SEQ ID NO: 99), RVDIHPF (SEQ ID NO: 100), RVYAHPF (SEQ ID NO: 101), RVYNHPF (SEQ ID NO: 102), RVYDHPF (SEQ ID NO: 103), RVYHHPF (SEQ ID NO: 104), RVYSHPF (SEQ ID NO: 105), RVYIHPA (SEQ ID NO:107), RVYIHPL (SEQ ID NO: 109), AAYIHPF (SEQ ID NO: 111), RAAIHPF (SEQ ID NO: 112), RVAAHPF (SEQ ID NO: 113), RAYAHPF (SEQ ID NO: 114), RAAAHPF (SEQ ID NO: 115), AAAIHPF (SEQ ID NO: 118), AGYIHPF (SEQ ID NO: 121), AHYIHPF (SEQ ID NO: 122), PGYIHPF (SEQ ID NO:164), PAYIHPF (SEQ ID NO: 124), MGYIHPF (SEQ ID NO:125), MAYIHPF (SEQ ID NO: 126), MHYIHPF (SEQ ID NO: 127), GGYIHPF (SEQ ID NO: 128), GAYIHPF (SEQ ID NO: 129), GHYIHPF (SEQ ID NO: 130), PVAIHPF (SEQ ID NO: 131), PVSIHPF (SEQ ID NO: 132), MVAIHPF (SEQ ID NO: 133), MVSIHPF (SEQ ID NO: 134), RGAIHPF (SEQ ID NO:156), RHAIHPF (SEQ ID NO: 136), RGYAHPF (SEQ ID NO: 137), RGYDHPF (SEQ ID NO: 138), RGYHHPF (SEQ ID NO: 139), RGYSHPF (SEQ ID NO: 140), RGYNHPF (SEQ ID NO: 141), RAYDHPF (SEQ ID NO: 142), RAYHHPF (SEQ ID NO: 143), RAYSHPF (SEQ ID NO: 144), RAYNHPF (SEQ ID NO: 145), RHYAHPF (SEQ ID NO: 146), RHYSHPF (SEQ ID NO: 147), RHYNHPF (SEQ ID NO: 148), RHYDHPF (SEQ ID NO: 149), RHYHHPF (SEQ ID NO: 150), RGADHPF (SEQ ID NO: 152), RGAHHPF (SEQ ID NO: 153), RHADHPF (SEQ ID NO: 155), RHSIHPF (SEQ ID NO:157), PGAIHPF (SEQ ID NO:159), RHAIHPF (SEQ ID NO: 136), PGSIHPF (SEQ ID NO:161), MGAIHPF (SEQ ID NO:162), MGSIHPF (SEQ ID NO:163), RGSIHPF (SEQ ID NO:166), PHAIHPF (SEQ ID NO:167), MHAIHPF (SEQ ID NO:168), PHSIHPF (SEQ ID NO:169), MHSIHPF (SEQ ID NO:170), GYIHPF (SEQ ID NO:171), AYIHPF (SEQ ID NO:172), HYIHPF (SEQ ID NO:190), VYAHPF (SEQ ID NO:176), VYNHPF (SEQ ID NO:177), VYDHPF (SEQ ID NO:178), VYHHPF (SEQ ID NO:179), VYSHPF (SEQ ID NO:180), VYIHPA (SEQ ID NO:182), VYIHPL (SEQ ID NO:184), AAIHPF (SEQ ID NO:186), AYAHPF (SEQ ID NO:188), HYIHPF (SEQ ID NO:190), GAIHPF (SEQ ID NO:192), HAIHPF (SEQ ID NO:193), GYAHPF (SEQ ID NO:194), GYDHPF (SEQ ID NO:195), GYHHPF (SEQ ID NO:196), GYSHPF (SEQ ID NO:197), GYNHPF (SEQ ID NO:198), AYDHPF (SEQ ID NO:199), AYHHPF (SEQ ID NO:200), AYSHPF (SEQ ID NO:201), AYNHPF (SEQ ID NO:202), HYAHPF (SEQ ID NO:203), HYSHPF (SEQ ID NO:204), HYNHPF (SEQ ID NO:205), HYDHPF (SEQ ID NO:206), HYHHPF (SEQ ID NO:207), GAIHPF (SEQ ID NO:192), HSIHPF (SEQ ID NO:214), GSIHPF (SEQ ID NO:216), HAIHPF (SEQ ID NO:193), AIHPF (SEQ ID NO:218), SIHPF (SEQ ID NO:219), DIHPF (SEQ ID NO:220), YAHPF (SEQ ID NO:221), YNHPF (SEQ ID NO:222), YDHPF (SEQ ID NO:223), YHHPF (SEQ ID NO:224) and YSHPF (SEQ ID NO:225). 
     
     
         3 . The pharmaceutical composition Vaccine according to  claim 1 , wherein at least one cysteine residue is bound to the N-terminus of the amino acid sequence according to Formula I. 
     
     
         4 . The pharmaceutical composition according to  claim 1 , wherein said carrier is a protein carrier. 
     
     
         5 . The pharmaceutical composition according to  claim 4 , wherein said protein carrier is selected from the group consisting of keyhole limpet haemocyanin (KLH), tetanus toxoid (TT) and diphtheria toxin (DT). 
     
     
         6 . The pharmaceutical composition according to  claim 1 , wherein said composition further comprises an adjuvant. 
     
     
         7 . The pharmaceutical composition according to  claim 1 , wherein said physical disorder associated with the renin-activated angiotensin system is selected from the group consisting of hypertension, stroke, infarction, kidney failure, congestive heart failure, atherosclerosis, vascular damage, retinal hemorrhage, and autoimmune diseases, and multiple sclerosis. 
     
     
         8 . (canceled) 
     
     
         9 . The pharmaceutical composition according to  claim 6 , wherein said adjuvant is alum. 
     
     
         10 . A method for treating a patient having or being at risk of a physical disorder associated with the renin-activated angiotensin system, wherein an efficient amount of a composition according to any one of  claim 1  is administered to said patient. 
     
     
         11 . The method according to  claim 10 , wherein said physical disorder associated with the renin-activated angiotensin system is hypertension or a hypertension-associated disease. 
     
     
         12 . The method according to  claim 10 , wherein said physical disorder associated with the renin-activated angiotensin system is selected from the group consisting of hypertension, stroke, infarction, kidney failure, congestive heart failure, atherosclerosis, vascular damage, retinal hemorrhage and an autoimmune disease wherein the autoimmune disease is multiple sclerosis.